Candel Therapeutics, Inc.CADLNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+10.8%
5Y CAGR+27.8%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+10.8%/yr
Annual compound
5Y CAGR
+27.8%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
3.4x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$47.42M+46.4%
2024$32.38M+124.7%
2023$14.41M-58.6%
2022$34.85M+209.6%
2021$11.26M-19.2%
2020$13.94M+445.4%
2019$2.56M-